{"organizations": [], "uuid": "cf1c55af2615f12a7b5b384307c2eb55db65e011", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/15", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-vermillion-to-report-first-quarter-2018-financial-results-on-monday-may-14.html", "country": "US", "domain_rank": 767, "title": "Vermillion to Report First Quarter 2018 on Monday, May 14", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.016, "site_type": "news", "published": "2018-05-04T00:01:00.000+03:00", "replies_count": 0, "uuid": "cf1c55af2615f12a7b5b384307c2eb55db65e011"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-vermillion-to-report-first-quarter-2018-financial-results-on-monday-may-14.html", "ord_in_thread": 0, "title": "Vermillion to Report First Quarter 2018 on Monday, May 14", "locations": [], "entities": {"persons": [{"name": "vermillion", "sentiment": "none"}], "locations": [{"name": "austin", "sentiment": "none"}, {"name": "texas", "sentiment": "none"}], "organizations": [{"name": "vermillion, inc.", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "AUSTIN, Texas, May 03, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.\nMonday, May 14th @ 4:30pm Eastern Time Domestic: 800-239-9838 International: 323-794-2551 Conference ID: 5200441 Webcast: http://public.viavid.com/index.php?id=129615 Replays, Available through May 28:\nDomestic: 844-512-2921 International: 412-317-6671 Replay PIN: 5200441 About Vermillion\nVermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.\nInvestor Relations Contact:\nAshley R. Robinson\nLifeSci Advisors, LLC\nTel 617-535-7742\nArr@lifesciadvisors.com\nSource:Vermillion, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/53f06b5d-b02e-4d0b-944c-b67250fe6d73", "http://public.viavid.com/index.php?id=129615"], "published": "2018-05-04T00:01:00.000+03:00", "crawled": "2018-05-04T01:28:53.010+03:00", "highlightTitle": ""}